17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The history of tuberculosis: from the first historical records to the isolation of Koch's bacillus

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Tuberculosis (TB) is a contagious, infectious disease, due to Mycobacterium tuberculosis (MT) that has always been a permanent challenge over the course of human history, because of its severe social implications. It has been hypothesized that the genus Mycobacterium originated more than 150 million years ago. In the Middle Ages, scrofula, a disease affecting cervical lymph nodes, was described as a new clinical form of TB. The illness was known in England and France as "king's evil", and it was widely believed that persons affected could heal after a royal touch. In 1720, for the first time, the infectious origin of TB was conjectured by the English physician Benjamin Marten, while the first successful remedy against TB was the introduction of the sanatorium cure. The famous scientist Robert Koch was able to isolate the tubercle bacillus and presented this extraordinary result to the society of Physiology in Berlin on 24 March 1882. In the decades following this discovery, the Pirquet and Mantoux tuberculin skin tests, Albert Calmette and Camille Guérin BCG vaccine, Selman Waksman streptomycin and other anti-tuberculous drugs were developed.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          History of BCG Vaccine.

          Tuberculosis (TB) is still responsible for 2 million deaths every year despite being a treatable airborne infectious disease. "Consumption" and "Phthisis" were terms historically used to describe TB, which was responsible for one in four deaths in the 19th century. Due to its infectious nature, chronic progression and long treatment, TB is a great burden for society. Moreover the emergence of multi-drug resistant TB and the current TB-HIV epidemic has raised even greater concern. Treating and preventing TB has become a permanent challange since the ancient times. Bacille Calmette-Guérin (BCG) is the only vaccine available today and has been used for more than 90 years with astonishing safety records. However, its efficacy remains controversial. No universal BCG vaccination policy exists, with some countries merely recommending its use and others that have implemented immunization programs. In this article we review several important milestones of BCG vaccine development from the discovery till today.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Rene Theophile Hyacinthe Laënnec (1781-1826): the man behind the stethoscope.

            A Roguin (2006)
            Rene Theophile Hyacinthe Laënnec (1781-1826) was a French physician who, in 1816, invented the stethoscope. Using this new instrument, he investigated the sounds made by the heart and lungs and determined that his diagnoses were supported by the observations made during autopsies. Laënnec later published the first seminal work on the use of listening to body sounds, De L'auscultation Mediate (On Mediate Auscultation). Laënnec is considered the father of clinical auscultation and wrote the first descriptions of bronchiectasis and cirrhosis and also classified pulmonary conditions such as pneumonia, bronchiectasis, pleurisy, emphysema, pneumothorax, phthisis and other lung diseases from the sounds he heard with his invention. Laënnec perfected the art of physical examination of the chest and introduced many clinical terms still used today.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Eliminating human tuberculosis in the twenty-first century.

              Recognizing that tuberculosis (TB) is still the leading cause of human death from a curable infection, the international health community has set ambitious targets for disease control. One target is to eliminate TB by 2050; that is, to cut the annual incidence of new cases to less than 1 per million population. National TB control programmes are working to eliminate TB mainly by intensifying efforts to find and cure patients with active disease. Here, we use mathematical modelling to show that, while most TB patients can be cured with present drug regimens, the 2050 target is far more likely to be achieved with a combination of diagnostics, drugs and vaccines that can detect and treat both latent infection and active disease. We find that the coupling of control methods is particularly effective because treatments for latent infection and active disease act in synergy. This synergistic effect offers new perspectives on the cost-effectiveness of treating latent TB infection and the impact of possible new TB vaccines. Our results should be a stimulus to those who develop, manufacture and implement new technology for TB control, and to their financial donors.
                Bookmark

                Author and article information

                Journal
                J Prev Med Hyg
                J Prev Med Hyg
                Pacini
                Journal of Preventive Medicine and Hygiene
                Pacini Editore SRL
                1121-2233
                2421-4248
                March 2017
                : 58
                : 1
                : E9-E12
                Affiliations
                [1 ] Department of Health Sciences, University of Genoa, Genoa, Italy;
                [2 ] Department of Cardiovascular, Dysmetabolic and Ageingassociated Diseases, Istituto Superiore di Sanità (Italian National Institute of Health), Rome, Italy;
                [3 ] Department of Health Sciences, University of Genoa, Section of History of Medicine and Ethics, Genoa, Italy
                Author notes
                Correspondence: Ilaria Barberis, Department of Health Sciences (DISSAL), University of Genoa, via A. Pastore 1, 16132 Genoa, Italy - Tel./ Fax +39 010 3538502 - E-mail: ilaria.barberis@ 123456hotmail.it

                Authors' Contributions

                MM conceived and designed the overview. IB and LG performed a search of the literature and contributed to the draft of the article. NLB revised critically the manuscript. MM supervised the manuscript. All authors read and approved the final version of the manuscript.

                Article
                Pacini
                10.15167/2421-4248/jpmh2017.58.1.728
                5432783
                28515626
                e89ef314-3af5-4f10-bd42-4f164d894bc6
                © Copyright by Pacini Editore SRL, Pisa, Italy

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License, which permits for noncommercial use, distribution, and reproduction in any digital medium, provided the original work is properly cited and is not altered in any way. For details, please refer to http://creativecommons.org/licenses/by-nc-nd/3.0/

                History
                : 07 December 2016
                : 14 January 2017
                Categories
                Overview

                tuberculosis,history,koch's bacillus
                tuberculosis, history, koch's bacillus

                Comments

                Comment on this article